Skip to main content
. 2015 Dec 1;34(6):418–422. doi: 10.1089/mab.2015.0034

FIG. 4.

FIG. 4.

Rat anti-EGFR antibody and cetuximab competition assay. (A) A431 cells were treated with 5 μg/mL of rat anti-EGFR antibody (2C2D3 or 4H7F4) in the presence or absence of 5 μg/mL of cetuximab. After washing, cells were treated with Alexa 488-conjugated anti-rat IgG antibody. (B) A431 cells were treated with 5 μg/mL of cetuximab in the presence or absence of 5 μg/mL of 2C2D3 or 4H7F4. After washing, cells were treated with FITC-conjugated anti-human IgG antibody. All stained cells were analyzed by flow cytometry. Mean fluorescence intensity (MFI) was calculated by subtracting the background MFI (no treatment with primary antibody) from the experimental MFI.